Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

icarus666/Moment via Getty Images In my coverage of Arrowhead Pharmaceuticals (ARWR) last February, I noted that my primary problem with ARWR is a lack of focus. Just look at this pipeline: ARWR PIPELINE (ARWR WEBSITE) There are, if I am counting it right, some 16 programs in the clinic, and frankly, this is too much. Like I noted last time, they should probably have focused on getting one product through the finishing line. Then, this long-tailed pipeline would have been an asset. If you want a good tail, ...